Portage Biotech (PRTG) reported late Thursday "encouraging" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with anti-PD-1 antibody.
The data showed both single agent activity, and more than 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma, it said.
"This is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor," Portage said, adding that it's making preparations to start a first-in-human trial.
The shares more than doubled in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。